Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:GSK-3β_inhibitor |
| gptkbp:CASNumber |
280744-09-4
|
| gptkbp:criteria |
selective for GSK-3β over other kinases
|
| gptkbp:discoveredBy |
GlaxoSmithKline
|
| gptkbp:firstDescribed |
2001
|
| gptkbp:hasInChIKey |
QZQJXGZQJXQKQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C17H12Cl2N2O2
|
| gptkbp:hasSMILES |
CN1C=CC2=C1C=CC(=C2)C3=CC(=O)N(C4=CC=C(C=C4)Cl)C3=O
|
| gptkbp:inhibitedBy |
GSK-3β activity
|
| gptkbp:IUPACName |
gptkb:3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
|
| gptkbp:mechanismOfAction |
ATP-competitive inhibitor
|
| gptkbp:molecularWeight |
347.20 g/mol
|
| gptkbp:PubChem_CID |
5311293
CHEMBL12360 |
| gptkbp:studiedBy |
gptkb:cancer
gptkb:diabetes stem cell biology neurodegenerative diseases |
| gptkbp:target |
gptkb:Glycogen_synthase_kinase-3_beta
|
| gptkbp:bfsParent |
gptkb:SB-216763
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
GSK-3β inhibitor SB-216763
|